BioCentury
ARTICLE | Clinical News

MBN-101: Phase IIa started

June 27, 2016 7:00 AM UTC

Microbion began a single-blind, placebo-controlled, U.S. Phase IIa trial to evaluate single doses of 0.5, 1.5 and 5 ug/cm 2 MBN-101 applied intraoperatively to infected osteosynthesis sites in about 3...